FIELD: biotechnology.
SUBSTANCE: polypeptide with cytotoxic activity, comprising an Fc region of IgG, which consists of a heterodimer containing the first polypeptide and the second polypeptide, in the amino acid sequences of which a series of mutations takes place. A pharmaceutical composition for treatment of a human disease associated with antigens with which the said polypeptide specifically interacts, comprising the said polypeptide and a medically acceptable carrier, is provided.
EFFECT: group of inventions allows to optimize the effector function of the polypeptide by changing the function of the Fc region compared to the function of the Fc region of the polypeptide, which consists of a homodimer containing only the first or only the second polypeptide.
7 cl, 54 dwg, 80 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETERODIMERISED POLYPEPTIDE | 2012 |
|
RU2719132C2 |
| FcγRIIb-SPECIFIC Fc-ANTIBODY | 2012 |
|
RU2608504C2 |
| METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
| METHOD OF CHANGING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2799423C1 |
| ANTIGEN-BINDING MOLECULE FOR ACCELERATING ANTIGEN LOSS | 2012 |
|
RU2772771C1 |
| ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FCΓRIIB | 2013 |
|
RU2736349C2 |
| VERSIONS OF FCΓRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2729831C2 |
| ANTIGEN-BINDING MOLECULE TO ACCELERATE ANTIGEN DISAPPEARANCE THROUGH FcγRIIB | 2013 |
|
RU2812226C1 |
| ANTIBODY Fc VARIANTS | 2012 |
|
RU2607014C2 |
| OPTIMIZED Fc-VERSIONS THAT HAVE ALTERED BINDING TO FcγR AND METHODS FOR THEIR PRODUCTION | 2004 |
|
RU2337107C2 |
